CorMedix Set for Breakout with DefenCath's Outpatient Launch
AI Prediction of CorMedix Inc. (CRMD)
CorMedix, a biopharmaceutical company focused on developing and commercializing therapeutic products, shows promise with its lead product, DefenCath. Recent FDA approval and subsequent commercial launch plans indicate potential growth. The upcoming PDUFA date and commercial roll-out in outpatient settings could serve as significant catalysts, impacting the stock positively.
CRMD Report Information
Prediction Date2025-07-03
Close @ Prediction$11.62
Mkt Cap639m
IPO DateN/a
AI-derived Information
Recent News for CRMD
- Aug 13, 9:04 pm — CorMedix Inc. Q2 2026 Earnings Call Summary (Moby)
- Aug 13, 7:08 pm — Cormedix Inc (CRMD) (Q2 2026) Earnings Call Highlights: Record Revenue and Raised EBITDA ... (GuruFocus.com)
- Aug 13, 11:04 am — CorMedix CEO Expects Supplemental Filing For Fungal Disease Treatment By Q3 CRMD Stock Sees Best Day In Nearly 10 Months After Earnings Beat (Stocktwits)
- Aug 13, 8:07 am — CRMD SEC filing points to financing activity (ScanScor Filing Bot)
- Aug 13, 7:40 am — CorMedix: Q2 Earnings Snapshot (Associated Press)
- Aug 13, 7:32 am — CRMD files 8-K with clinical-trial language (ScanScor Filing Bot)
- Aug 13, 7:30 am — Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire RSS)
- Aug 7, 4:18 pm — CRMD SEC filing points to financing activity (ScanScor Filing Bot)
- Jul 29, 8:30 am — CorMedix Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 13, 2026 (GlobeNewswire RSS)
- Jun 8, 8:30 am — U.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in Minocin® Patent Litigation (GlobeNewswire RSS)
- May 15, 8:30 am — Cormedix Therapeutics to Participate in two Upcoming Investor Conferences (GlobeNewswire)
- May 14, 7:02 pm — Cormedix Inc (CRMD) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.